Gregory Gewirtz is counsel in the Mergers & Acquisitions practice.

Gregory has broad experience advising on public and private mergers and acquisitions, including carve-outs, divestitures, reorganizations, minority investments, joint ventures, and financial advisory assignments.

Gregory’s experience includes a secondment with The Dow Chemical Company’s corporate and financial law department in Midland, Michigan during the first half of 2013, and a rotation to the Hong Kong Mergers & Acquisitions practice from June 2017 to June 2018.

• Dow Chemical in numerous transactions, including in its $130 billion transaction with DuPont involving the combination of the two companies, the subsequent separation into three public companies and the resulting $50 billion spin-off of Dow Inc., its $5 billion Reverse Morris Trust transaction with Olin involving Dow’s chlor-alkali and derivatives business, matters relating to its $17.4 billion K-Dow joint venture with PIC, its $4.8 billion strategic ownership restructuring of Dow Corning, its $1.5 billion sale of its MEGlobal joint venture interest to EQUATE, its $1.63 billion sale of Trinseo to Bain Capital, its sale of its global polypropylene business to Braskem, its sale of its interest in Nippon Unicar to the Tonen Group, its sale of its acid copolymers and ionomers business to SK Global Chemical Co., its sale of its extruded polystyrene foam (XPS) business and its sale of its German S/A Latex business
• Celanese in numerous transactions, including in its $11 billion acquisition of the mobility and materials business of DuPont, its restructuring of its Korea Engineering Plastics joint venture with Mitsubishi Gas Chemical, its $1.575 billion divestiture of its interest in its Polyplastics joint venture to Daicel and its Nutrinova food ingredients joint venture with Mitsui
• Lanxess in numerous transactions, including in its acquisition of the clean and disinfect business of Chemours, its acquisition of the U.S. phosphorus additives business of Solvay, its acquisition of Emerald Kalama Chemical from American Securities and its acquisition of the microbial control business of IFF
• Dover in numerous transactions, including in its acquisition of FW Murphy Production Controls and its acquisition of Espy Corporation
• KMG Chemicals in its $1.6 billion sale to Cabot Microelectronics
• SPX Technologies in its divestiture of subsidiaries holding asbestos liabilities and related assets to a joint venture of Global Risk Capital and Premia Holdings and its related Section 251(g) reorganization
• Sasol in its sale of its 50% membership interest in its HDPE joint venture to INEOS
• The Chefs’ Warehouse in numerous transactions, including its acquisition of Chef Middle East and its acquisition of Greenleaf Produce
• Industrias Bachoco in numerous transactions, including in a tender offer by Edificio Del Noroeste for Industrias Bachoco’s Series B shares and NYSE-listed ADSs
• Oil Search in connection with its business combination with Santos pursuant to a Papua New Guinea scheme of arrangement
• Intapp in its $314 million IPO
• Temasek Holdings in its investment in Tencent Music Entertainment
• China Investment Corporation in its co-investment with Sycamore Partners in the take-private of Staples
• International Finance Corporation in its sales of shares in Bank South Pacific to the Fiji National Provident Fund and to the Samoa National Provident Fund
• Blue Pool Capital in its Series D investment in SECA
• Primavera Capital Group in its investment in Cainiao Smart Logistics Network Limited, the logistics arm of Alibaba Group
• ZZ Capital in its sales of its investments in Building Energy and Surgical Specialties to Aretex Capital Partners
• Tiger Group Investments in connection with its sale of its Greater China Intermodal joint venture with The Carlyle Group and other members to Seaspan
• The Special Committee of the Board of Directors of Sohu.com Inc. in connection with the acquisition of all outstanding shares (including shares represented by American depositary shares) in its majority-owned subsidiary Changyou.com Limited by Dr. Charles Zhang, the Chairman and Chief Executive Officer of Sohu and the Chairman of the Board of Changyou.com
• HeartWare International in numerous transactions, including its acquisitions of World Heart Corporation and CircuLite and its proposed sale to Thoratec
• Danone in its acquisitions of YoCream International and YoCrunch
• Sun Pharmaceutical in its attempted going-private transaction of its controlled subsidiary Taro Pharmaceutical
• Grupo Sura in its co-investment transactions in connection with its acquisition of ING’s Latin American pensions, life insurance and investment management operations, with affiliates of each of General Atlantic Partners, International Finance Corporation, and J.P. Morgan Chase & Co.
• BE Aerospace in numerous transactions, including its acquisition of the TSI Group and another unannounced acquisition
• Northgate Capital in its sale of a majority interest to Religare Enterprises
• WebMD in its sale of Porex Corporation
• NASDAQ OMX Group in its joint bid, together with Intercontinental Exchange, for NYSE Euronext and in its acquisition of TruEquity
• Intercontinental Exchange in numerous transactions, including in matters relating to its acquisition of the New York Stock Exchange and its partnership with Cetip
• Liberty Global in numerous transactions, including its creation of its “LiLaC” tracking stock under English law
• Merrill Lynch & Co. in its sale to Bank of America Corporation
• Bank of America Corporation, Barclays Capital, Centerview Partners, Credit Suisse, Evercore Group, J.P. Morgan, Morgan Stanley, and Perella Weinberg Partners when acting as financial advisor

Selected Publications

• Co-Author, “Changing Its Mind: A Board’s Prerogative?, “ The M&A Lawyer, September 2015
• Co-Author, “Dusting Off Appraisal Rights: The Development of a New Investment Strategy,” The M&A Lawyer, April 2014